The Brain-Derived Neurotrophic Factor Val66Met Polymorphism and Prediction of Neural Risk for Alzheimer Disease
Authors:
- Aristotle N. VoineskosAVAristotle N. Voineskos
- Jason P. LerchJLJason P. Lerch
- Daniel FelskyDFDaniel Felsky
- Sajid ShaikhSSSajid Shaikh
- Tarek K. RajjiTRTarek K. Rajji
- Dielle MirandaDMDielle Miranda
- Nancy J. LobaughNLNancy J. Lobaugh
- Benoit H. MulsantBMBenoit H. Mulsant
- Bruce G. PollockBPBruce G. Pollock
- James L. KennedyJKJames L. Kennedy
Open Access
- 7 February 2011
- journal article
- research article
- Published by American Medical Association (AMA) in Archives of General Psychiatry
- Vol. 68 (2) , 198-206
Abstract
Sporadic or late-onset Alzheimer disease (AD) constitutes 90% to 95% of AD cases and is a complex, heterogeneous disorder with increasing prevalence.1 Although some notable examples of genetic risk in AD have been established2 and some promising data from genome-wide studies have emerged,3,4 genetic investigations in this disorder have been fraught with many of the same complexities and conundrums as those of other neuropsychiatric disorders.5 The brain-derived neurotrophic factor (BDNF) gene represents an intriguing potential genetic mechanism for risk of late-onset AD.6 Brain-derived neurotrophic factor is critical for neuronal plasticity and facilitates hippocampal and cortical long-term potentiation,7 processes that are especially important for learning and memory. Learning and memory processes are substantially affected in AD, arising largely from impaired neuronal plasticity.8 In AD patients, BDNF expression is prominently reduced in the hippocampus and the entorhinal cortex,9 and these regions are consistently affected in the earliest stages of the disease.10,11 Variation in the BDNF Val66Met (rs6265, G>A) polymorphism has been shown to be related to episodic memory performance in younger adults via the hippocampal formation, where methionine (Met) allele carriers had poorer episodic memory performance.12 In addition, this polymorphism predicts cognitive performance in elderly individuals13 and may confer risk for AD,14 where valine/valine (Val/Val) individuals in these 2 studies were at risk. Recent animal model findings suggest a compelling potential role for BDNF as a therapeutic agent in AD.15 Taken together, these findings suggest that BDNF gene variation may be a genetic susceptibility mechanism for AD.Keywords
This publication has 41 references indexed in Scilit:
- Age-related decline in white matter tract integrity and cognitive performance: A DTI tractography and structural equation modeling studyNeurobiology of Aging, 2012
- Multiple indicators of age-related differences in cerebral white matter and the modifying effects of hypertensionNeuroImage, 2010
- Neural stem cells improve cognition via BDNF in a transgenic model of Alzheimer diseaseProceedings of the National Academy of Sciences, 2009
- Distinct patterns of brain activity in young carriers of the APOE -ε4 alleleProceedings of the National Academy of Sciences, 2009
- Quantitative examination of a novel clustering method using magnetic resonance diffusion tensor tractographyNeuroImage, 2009
- BDNF val66met polymorphism influences age differences in microstructure of the corpus callosumFrontiers in Human Neuroscience, 2009
- Effect of BDNF val66met polymorphism on age-related amygdala volume changes in healthy subjectsProgress in Neuro-Psychopharmacology and Biological Psychiatry, 2008
- Diffusion tensor imaging of cingulum fibers in mild cognitive impairment and Alzheimer diseaseNeurology, 2007
- Orthogonal tensor invariants and the analysis of diffusion tensor magnetic resonance imagesMagnetic Resonance in Medicine, 2005
- Efficiency and power in genetic association studiesNature Genetics, 2005